OncoMed Pharmaceuticals Inc logo

OMED - OncoMed Pharmaceuticals Inc Share Price

$0.89 0.0  0.0%

Last Trade - 22/04/19

Sector
Healthcare
Size
Micro Cap
Market Cap £n/a
Enterprise Value £n/a
Revenue £35.3m
Position in Universe th / 6316
Bullish
Bearish
Unlock OMED Revenue
Momentum
Relative Strength (%)
1m
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High
50d MA
200d MA
Margin of Safety
Qualifying GuruScreens
Financial Summary
FINANCIAL BRIEF: : For the fiscal year ended 31 December 2018, Oncomed Pharmaceuticals Inc revenues increased 16% to $44.4M. Net loss before extraordinary items decreased 80% to $8.1M. Revenues reflect Collaboration revenue increase of 23% to $44.4M. Lower net loss reflects Research and Development - other decrease of 43% to $31.1M (expense), Stock-based Compensation in R&D decrease of 31% to $3.4M (expense).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

OMED Revenue Unlock OMED Revenue

Net Income

OMED Net Income Unlock OMED Revenue

Normalised EPS

OMED Normalised EPS Unlock OMED Revenue

PE Ratio Range

OMED PE Ratio Range Unlock OMED Revenue

Dividend Yield Range

OMED Dividend Yield Range Unlock OMED Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2020
31st Dec 2021
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
OMED EPS Forecasts Unlock OMED Revenue
Profile Summary

OncoMed Pharmaceuticals, Inc. (OncoMed) is a clinical-stage biopharmaceutical company. The Company focuses on discovering and developing therapeutics that address the fundamental biology driving cancer's growth, resistance, recurrence and metastasis. The Company's therapeutic candidates and preclinical programs include Demcizumab (Anti-DLL4, OMP-21M18), Tarextumab (Anti-Notch2/3, OMP-59R5), Vantictumab (anti-Fzd7, OMP-18R5), Ipafricept (Fzd8-Fc, OMP-54F28), Brontictuzumab (Anti-Notch1, OMP-52M51), Navicixizumab (Anti-DLL4/VEGF Bispecific, OMP-305B83), Anti-RSPO3 (OMP-131R10), Anti-TIGIT (OMP-313M32) and GITRL-Fc trimer (OMP-336B11). Demcizumab is a humanized monoclonal antibody that inhibits Delta-like Ligand 4 (DLL4) in the Notch signaling pathway. Tarextumab is a human monoclonal antibody that binds to both the Notch2 and Notch3 receptors.

Directors
Last Annual December 31st, 2018
Last Interim December 31st, 2018
Incorporated July 19, 2004
Public Since July 17, 2013
No. of Shareholders: 44
No. of Employees: 22
Sector Healthcare
Industry Biotechnology & Medical Research
Index
Exchange NASDAQ Global Select Market
Shares in Issue 38,690,089
Free Float (0.0%)
Eligible for
ISAs
SIPPs
OMED Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for OMED
Upcoming Events for OMED
Frequently Asked Questions for OncoMed Pharmaceuticals Inc
What is the OncoMed Pharmaceuticals Inc share price?

As of 22/04/19, shares in OncoMed Pharmaceuticals Inc are trading at $0.89, giving the company a market capitalisation of £n/a. This share price information is delayed by 15 minutes.

How has the OncoMed Pharmaceuticals Inc share price performed this year?

Shares in OncoMed Pharmaceuticals Inc are currently trading at $0.89 and the price has moved by -71.84% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the OncoMed Pharmaceuticals Inc price has moved by -74.16% over the past year.

What are the analyst and broker recommendations for OncoMed Pharmaceuticals Inc?

Of the analysts with advisory recommendations for OncoMed Pharmaceuticals Inc, there are there are currently 0 "buy" , 2 "hold" and 0 "sell" recommendations. The overall consensus recommendation for OncoMed Pharmaceuticals Inc is Hold. You can view the full broker recommendation list by unlocking its StockReport.

When will OncoMed Pharmaceuticals Inc next release its financial results?

OncoMed Pharmaceuticals Inc is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2019-12-31
What is the OncoMed Pharmaceuticals Inc dividend yield?

OncoMed Pharmaceuticals Inc does not currently pay a dividend.

Does OncoMed Pharmaceuticals Inc pay a dividend?

OncoMed Pharmaceuticals Inc does not currently pay a dividend.

When does OncoMed Pharmaceuticals Inc next pay dividends?

OncoMed Pharmaceuticals Inc does not currently pay a dividend.

How do I buy OncoMed Pharmaceuticals Inc shares?

To buy shares in OncoMed Pharmaceuticals Inc you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of OncoMed Pharmaceuticals Inc?

Shares in OncoMed Pharmaceuticals Inc are currently trading at $0.89, giving the company a market capitalisation of £n/a.

Where are OncoMed Pharmaceuticals Inc shares listed? Where are OncoMed Pharmaceuticals Inc shares listed?

Here are the trading details for OncoMed Pharmaceuticals Inc:

Country of listing: United States
Exchange: NSQ
Ticker Symbol: OMED
What kind of share is OncoMed Pharmaceuticals Inc?

We were not able to load our ranking data for OncoMed Pharmaceuticals Inc

Is there a OncoMed Pharmaceuticals Inc share price forecast 2020?

We were not able to load any forecast data for OncoMed Pharmaceuticals Inc.

How can I tell whether the OncoMed Pharmaceuticals Inc share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like OncoMed Pharmaceuticals Inc. Over the past six months, the relative strength of its shares against the market has been -50.91%. At the current price of $0.89, shares in OncoMed Pharmaceuticals Inc are trading at % against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the OncoMed Pharmaceuticals Inc PE Ratio?

We were not able to find PE ratio data for OncoMed Pharmaceuticals Inc.

Who are the key directors of OncoMed Pharmaceuticals Inc?

We were unable to find the directors for OncoMed Pharmaceuticals Inc.

Who are the major shareholders of OncoMed Pharmaceuticals Inc?

Here are the top five shareholders of OncoMed Pharmaceuticals Inc based on the size of their shareholding:

Similar to OMED
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.